Repeated High-dose Inhaled Corticosteroids for Asthma

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00695604

Acronym

ReHICS

Enrollment

Registered

2008-06-12

Start date

2008-05-31

Completion date

2011-09-30

Last updated

2018-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Acute asthma, fluticasone, inhaled corticosteroids

Brief summary

The purpose of this study is to to compare the effects of high-dose Inhaled Corticosteroids (ICS) vs. placebo in adults with chronic stable asthma.

Interventions

DRUGPlacebo

Placebo via MDI.

DRUGFluticasone

Fluticasone MDI.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Physician diagnosis of asthma. * Age ≥18 years and ≤50 years * Evidence of airflow obstruction as measured by spirometry and flow-volume loop per American Thoracic Society guidelines. * Treatment for asthma with: * daily inhaled corticosteroids and long-acting beta2-agonists, AND * as-needed use of a short-acting beta2-agonist

Exclusion criteria

* History of \>10 pack-year tobacco use * Other pulmonary or cardiac diagnosis that is actively being treated * History of adverse events or allergy to fluticasone * Systemic corticosteroid therapy within 7 days of study visit * Inability to obtain written informed consent

Design outcomes

Primary

Measure	Time frame
Airflow inflammation.	Pre-study and post-study drug administration

Secondary

Measure	Time frame
Airflow obstruction.	Pre-study and post-study drug administration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026